Your browser doesn't support javascript.
loading
A Streptococcus pneumoniae lineage usually associated with pneumococcal conjugate vaccine (PCV) serotypes is the most common cause of serotype 35B invasive disease in South Africa, following routine use of PCV.
Ndlangisa, Kedibone M; du Plessis, Mignon; Lo, Stephanie; de Gouveia, Linda; Chaguza, Chrispin; Antonio, Martin; Kwambana-Adams, Brenda; Cornick, Jennifer; Everett, Dean B; Dagan, Ron; Hawkins, Paulina A; Beall, Bernard; Corso, Alejandra; Grassi Almeida, Samanta Cristine; Ochoa, Theresa J; Obaro, Stephen; Shakoor, Sadia; Donkor, Eric S; Gladstone, Rebecca A; Ho, Pak Leung; Paragi, Metka; Doiphode, Sanjay; Srifuengfung, Somporn; Ford, Rebecca; Moïsi, Jennifer; Saha, Samir K; Bigogo, Godfrey; Sigauque, Betuel; Eser, Özgen Köseoglu; Elmdaghri, Naima; Titov, Leonid; Turner, Paul; Kumar, K L Ravi; Kandasamy, Rama; Egorova, Ekaterina; Ip, Margaret; Breiman, Robert F; Klugman, Keith P; McGee, Lesley; Bentley, Stephen D; von Gottberg, Anne.
Afiliação
  • Ndlangisa KM; National Institute for Communicable Diseases (NICD), a division of the National Health Laboratory Service, Johannesburg, South Africa.
  • du Plessis M; National Institute for Communicable Diseases (NICD), a division of the National Health Laboratory Service, Johannesburg, South Africa.
  • Lo S; School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
  • de Gouveia L; Parasites and Microbes, Wellcome Sanger Institute, Hinxton, UK.
  • Chaguza C; National Institute for Communicable Diseases (NICD), a division of the National Health Laboratory Service, Johannesburg, South Africa.
  • Antonio M; Parasites and Microbes, Wellcome Sanger Institute, Hinxton, UK.
  • Kwambana-Adams B; WHO Collaborating Centre for New Vaccines Surveillance, Medical Research Council Unit, The Gambia at London School of Hygiene & Tropical Medicine, Fajara, The Gambia.
  • Cornick J; NIHR Global Health Research Unit on Mucosal Pathogens, Division of Infection and Immunity, University College London, London, UK.
  • Everett DB; West Africa Partnerships and Strategies, Medical Research Council Unit The Gambia at The London School of Hygiene and Tropical Medicine, Fajara, Gambia.
  • Dagan R; Malawi-Liverpool-Wellcome-Trust, Blantyre, Malawi.
  • Hawkins PA; Malawi-Liverpool-Wellcome-Trust, Blantyre, Malawi.
  • Beall B; Centre for Inflammation Research, Queens Research Institute, University of Edinburgh, Edinburgh, UK.
  • Corso A; The Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Grassi Almeida SC; Rollins School Public Health, Emory University, Atlanta, USA.
  • Ochoa TJ; Centers for Disease Control and Prevention, Atlanta, USA.
  • Obaro S; Centers for Disease Control and Prevention, Atlanta, USA.
  • Shakoor S; Administración Nacional de Laboratorios e Institutos de Salud, Buenos Aires, Argentina.
  • Donkor ES; Center of Bacteriology, Adolfo Lutz Institute, São Paulo, Brazil.
  • Gladstone RA; Instituto de Medicina Tropical, Universidad Peruana Cayetano Heredia, Lima, Peru.
  • Ho PL; University of Nebraska Medical Center, Omaha, USA.
  • Paragi M; The Aga Khan University, Karachi, Pakistan.
  • Doiphode S; Department of Medical Microbiology, University of Ghana Medical School, Accra, Ghana.
  • Srifuengfung S; Parasites and Microbes, Wellcome Sanger Institute, Hinxton, UK.
  • Ford R; Department of Microbiology and Carol Yu Centre for Infection, The University of Hong Kong, Queen Mary Hospital, Hong Kong, PR China.
  • Moïsi J; National Laboratory of Health, Environment and Food, Ljubljana, Slovenia.
  • Saha SK; Hamad Medical Corporation, Doha, Qatar.
  • Bigogo G; Faculty of Pharmacy, Siam University, Bangkok, Thailand.
  • Sigauque B; Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.
  • Eser ÖK; Agence de Médecine Préventive, Paris, France.
  • Elmdaghri N; Child Health Research Foundation, Dhaka, Bangladesh.
  • Titov L; Kenya Medical Research Institute, Kisumu, Kenya.
  • Turner P; Centro de Investigação em Saúde da Manhiça, Maputo, Moçambique.
  • Kumar KLR; Hacettepe University Faculty of Medicine, Department of Medical Microbiology, Ankara, Turkey.
  • Kandasamy R; Faculty of Medicine and Pharmacy & Ibn Rochd University Hospital Center, Casablanca, Morocco.
  • Egorova E; The Republican Research and Practical Center for Epidemiology and Microbiology, Minsk, Belarus.
  • Ip M; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Breiman RF; Kempegowda Institute of Medical Sciences Hospital & Research Center, Bangalore, India.
  • Klugman KP; University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
  • McGee L; G. N. Gabrichevsky Research Institute for Epidemiology and Microbiology, Moscow, Russia.
  • Bentley SD; Department of Microbiology, Chinese University of Hong Kong, Hong Kong, PR China.
  • von Gottberg A; The Emory Global Health Institute, Atlanta, USA.
  • The Global Pneumococcal Sequencing Consortium; School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
Microb Genom ; 8(4)2022 04.
Article em En | MEDLINE | ID: mdl-35384831
ABSTRACT
Pneumococcal serotype 35B is an important non-conjugate vaccine (non-PCV) serotype. Its continued emergence, post-PCV7 in the USA, was associated with expansion of a pre-existing 35B clone (clonal complex [CC] 558) along with post-PCV13 emergence of a non-35B clone previously associated with PCV serotypes (CC156). This study describes lineages circulating among 35B isolates in South Africa before and after PCV introduction. We also compared 35B isolates belonging to a predominant 35B lineage in South Africa (GPSC5), with isolates belonging to the same lineage in other parts of the world. Serotype 35B isolates that caused invasive pneumococcal disease in South Africa in 2005-2014 were characterized by whole-genome sequencing (WGS). Multi-locus sequence types and global pneumococcal sequence clusters (GPSCs) were derived from WGS data of 63 35B isolates obtained in 2005-2014. A total of 262 isolates that belong to GPSC5 (115 isolates from South Africa and 147 from other countries) that were sequenced as part of the global pneumococcal sequencing (GPS) project were included for comparison. Serotype 35B isolates from South Africa were differentiated into seven GPSCs and GPSC5 was most common (49 %, 31/63). While 35B was the most common serotype among GPSC5/CC172 isolates in South Africa during the PCV13 period (66 %, 29/44), 23F was the most common serotype during both the pre-PCV (80 %, 37/46) and PCV7 period (32 %, 8/25). Serotype 35B represented 15 % (40/262) of GPSC5 isolates within the global GPS database and 75 % (31/40) were from South Africa. The predominance of the GPSC5 lineage within non-vaccine serotype 35B, is possibly unique to South Africa and warrants further molecular surveillance of pneumococci.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 4_TD Base de dados: MEDLINE Assunto principal: Infecções Pneumocócicas / Streptococcus pneumoniae Tipo de estudo: Risk_factors_studies Limite: Humans País/Região como assunto: Africa Idioma: En Revista: Microb Genom Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 4_TD Base de dados: MEDLINE Assunto principal: Infecções Pneumocócicas / Streptococcus pneumoniae Tipo de estudo: Risk_factors_studies Limite: Humans País/Região como assunto: Africa Idioma: En Revista: Microb Genom Ano de publicação: 2022 Tipo de documento: Article